In-hospital stroke and mortality trends after left ventricular assist device implantation in the United States from 2017 to 2019

Abstract

Background:

The newer Left Ventricular Assist Device (LVAD), the HeartMate 3 (HM3), was initially approved by the Food and Drug Administration in 2017. We aimed to describe the temporal trends of in-hospital stroke and mortality among patients who underwent LVAD placement between 2017 and 2019.

Methods:

The National Inpatient Sample was queried from 2017 to 2019 to identify all adults with heart failure and reduced ejection fraction (HFrEF) who underwent LVAD implantation using the International Classification of Diseases 10th Revision codes. The Cochran-Armitage test was conducted to assess the linear trend of in-hospital stroke and mortality. In addition, multivariable regression analysis was conducted to assess the association of LVAD placement with in-hospital stroke and death.

Results:

A total of 5,087,280 patients met the selection criteria. Of those, 11,750 (0.2%) underwent LVAD implantation. There was a downtrend in in-hospital mortality per year (trend: −1.8%, p = 0.03), but not in the trend of both ischemic and hemorrhagic stroke per year. LVAD placement was associated with greater odds of stroke of any type (OR = 1.96, 95% CI 1.68–2.29, p < 0.001) and in-hospital mortality (OR = 1.37, 95% CI 1.16–1.61, p < 0.001).

Conclusions:

Our study found a significant downtrend in the in-hospital mortality rates among patients with LVAD without substantial changes in stroke rate trends over the study timeframe. As stroke rates remained steady, we hypothesize that improved management along with better control of blood pressure, could have played an important role in survival benefit over the study time frame.

Keywords

Acute hemorrhagic stroke acute ischemic stroke mechanical inotropic support refractory heart failure ventricular assist devices

Get full access to this article

View all access options for this article.

References

Heidenreich

Bozkurt

Aguilar

, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail 2022; 28(5): e1–e167.

Mehra

Uriel

Naka

, et al. A fully magnetically levitated left ventricular assist device—final report. N Engl J Med 2019; 380(17): 1618–1627.

Food and Drug Administration (FDA). HeartMate 3TM left ventricular assist system premarket approval (PMA). Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160054 (2017, accessed 5 April 2022).

Teuteberg

Cleveland

Cowger

, et al. The society of thoracic Surgeons Intermacs 2019 annual report: the changing landscape of devices and indications. Ann Thorac Surg 2020; 109(3): 649–660.

World Health Organization (WHO). International Classification of Diseases (ICD). http://www.who.int/standards/classifications/classification-of-diseases (accessed 9 April 2022).

Healthcare Cost and Utilization Project (HCUP). NIS Overview. Rockville, Maryland: Agency for Healthcare Research and Quality. https://www.hcup-us.ahrq.gov/nisoverview.jsp (2021, 4 April 2022).

Molina

Shah

Kiernan

, et al. The society of thoracic surgeons intermacs 2020 annual report. Ann Thorac Surg 2021; 111(3): 778–792.

Mehra

Cleveland

Uriel

, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail 2021;23(8):1392–1400.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.63 MB